Hospice Claims and Deaths Within 180 Days of NaF PET, by Indication for Imaging, Cancer Type, and Scan Result
| Hospice claims | Deaths | ||||||||||
| Indication | Cancer type | Scan result | n | n | % | % difference | RR† | n | % | % difference | RR‡ |
| IS | Prostate | Positive | 530 | 24 | 4.5 | 3.9 | 6.7 | 31 | 5.8 | 4.7 | 5.1 |
| Probably positive | 295 | <11* | — | — | — | <11* | — | — | — | ||
| Negative | 3,247 | 22 | 0.7 | — | — | 37 | 1.1 | — | — | ||
| Lung | Positive | 81 | 29 | 35.8 | 23.6 | 2.9 | 45 | 55.6 | 35.8 | 2.8 | |
| Probably positive | 32 | <11* | — | — | — | 11 | 34.4 | 14.6 | 1.7 | ||
| Negative | 197 | 24 | 12.2 | — | — | 39 | 19.8 | — | — | ||
| Other cancers | Positive | 131 | 20 | 15.3 | 7.5 | 2.0 | 30 | 22.9 | 12.9 | 2.3 | |
| Probably positive | 50 | <11* | — | — | — | <11* | — | — | — | ||
| Negative | 592 | 46 | 7.8 | 59 | 10.0 | ||||||
| FOM | Prostate | Positive | 2,154 | 199 | 9.2 | 8.0 | 7.5 | 221 | 10.3 | 8.2 | 5.0 |
| Probably positive | 778 | 29 | 3.7 | 2.5 | 3.0 | 27 | 3.5 | 1.4 | 1.7 | ||
| Negative | 4,473 | 55 | 1.2 | 92 | 2.1 | ||||||
| Lung | Positive | 182 | 83 | 45.6 | 28.0 | 2.6 | 104 | 57.1 | 33.7 | 2.4 | |
| Probably positive | 64 | 16 | 25.0 | 7.4 | 1.4 | 20 | 31.3 | 7.8 | 1.3 | ||
| Negative | 341 | 60 | 17.6 | 80 | 23.5 | ||||||
| Breast | Positive | 308 | 29 | 9.4 | 6.7 | 3.5 | 31 | 10.1 | 7.1 | 3.4 | |
| Probably positive | 99 | <11* | — | — | — | <11* | — | — | — | ||
| Negative | 849 | 23 | 2.7 | 25 | 2.9 | ||||||
| Other cancers | Positive | 290 | 80 | 27.6 | 17.1 | 2.6 | 90 | 31.0 | 17.2 | 2.2 | |
| Probably positive | 102 | 19 | 18.6 | 8.2 | 1.8 | 27 | 26.5 | 12.7 | 1.9 | ||
| Negative | 630 | 66 | 10.5 | 87 | 13.8 | ||||||
| POM | Prostate | More extensive | 1,138 | 183 | 16.1 | 9.7 | 2.5 | 204 | 17.9 | 9.5 | 2.1 |
| No change/less extensive | 781 | 50 | 6.4 | 66 | 8.5 | ||||||
| Other cancers | More extensive | 400 | 89 | 22.3 | 10.3 | 1.9 | 88 | 22 | 9.8 | 1.8 | |
| No change/less extensive | 336 | 40 | 11.9 | 41 | 12.2 | ||||||
| TM | Prostate | Worse | 749 | 114 | 15.2 | 9.4 | 2.6 | 124 | 16.6 | 9.2 | 2.3 |
| No change/better | 1,351 | 79 | 5.8 | 99 | 7.3 | ||||||
| Other cancers | Worse | 285 | 71 | 24.9 | 13.8 | 2.2 | 82 | 28.8 | 16.4 | 2.3 | |
| No change/better | 702 | 78 | 11.1 | 87 | 12.4 | ||||||
↵* Virtual Data Research Center rules prohibit displaying cell counts < 11. No statistics have been computed from these values.
↵† P value is based on χ2 test, P < 0.0001 for all comparisons except IS for other cancers (P = 0.007) and POM for other cancers (P = 0.0002). Bonferroni-corrected threshold for significance is 0.05/11 = 0.0045 given that there were 11 comparisons.
↵‡ P value is based on χ2 test, P < 0.0001 for all comparisons, except POM for other cancers (P = 0.0005). Bonferroni-corrected threshold for significance is 0.05/11 = 0.0045 given that there were 11 comparisons.
RR = risk ratio. Referent group is “Negative scan” for IS and FOM, “No change/less extensive” for POM, and “No change/better” for TM.
Participants may appear in table multiple times but only once per imaging indication.